UK doctors embracing technology, but not for their patients, survey reveals
November 6, 2015Medical Communications, Research and Development
A global online survey of doctors released by market research agency Cello Health Insight has indicated that although UK doctors …
Top 5 pharma companies’ Q3 results
November 6, 2015Medical Communications, Sales and Marketing financial results, revenue, sales
The leading pharma players have been able to report largely positive financial results to their shareholders in the third quarter …
AstraZeneca acquires ZS Pharma for $2.7bn, announces Q3 results
November 6, 2015Medical Communications AstraZeneca, M&A, MA, ZS Pharma, ZS-9, acquisitions, financial results, hyperkalaemia, mergers
AstraZeneca has announced its acquisition of ZS Pharma for an all-cash total of $2.7 billion. In the latest mega-money deal …
Sanofi buys in new diabetes drug
November 6, 2015Medical Communications, Research and Development, Sales and Marketing Lexicon Pharma, SGLT2, SGLT2 inhibitors, Sanofi, sotagliflozin
Sanofi has paid an initial $300 million for collaboration and license agreement to develop sotagliflozin, one of a newer class …
Brandicourt sets out Sanofi’s long-term vision
November 6, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi, olivier brandicourt, pharma strategy
Sanofi has pledged to plough the money saved from its business restructure into R&D investment, to bring 18 new products …
Merck and Pfizer begin new Phase III avelumab trial in lung cancer
November 5, 2015Medical Communications, Research and Development Merck, Pfizer, avelumab, lung cancer, non-small cell lung cancer
Merck and Pfizer have commenced an international Phase III study of the investigational cancer immunotherapy avelumab in patients with non-small …
New treatments to boost dry eye drug market – if approved
November 5, 2015Sales and Marketing Allergan, Ikervis, Restasis, Shire, cyclosporine, dry eye disease, dry eye syndrome, lifitegrast
The global market for treatments for dry eye syndrome will double in value to an estimated $4.6 billion by 2024, …
Featured market report: Summary of dry eye syndrome
November 5, 2015dry eye disease, dry eye syndrome, lifitegrast
This report provides the current prevalent population for dry eye syndrome across seven major markets.It includes data for the USA, …
Sanofi and Hanmi partner to create long-acting diabetes treatments
November 5, 2015Manufacturing and Production, Research and Development Korea, Sanofi, diabetes, hanmi
Sanofi and Hanmi Pharmaceutical have announced a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments. Korea’s …
OECD report warns of high spend and slow growth for pharma industry
November 5, 2015Manufacturing and Production, Sales and Marketing OECD, pharmaceutical spending
The high prices that pharma companies charge for specialty medicines are straining the health budgets of wealthy nations, according to …
Obama government launches drug price crackdown
November 4, 2015Manufacturing and Production, Research and Development, Sales and Marketing Drug pricing, President Obama, US, affordability, market access
President Obama has launched an ‘Affordable Drug Pricing Task Force’, aimed at tackling the spiralling cost of certain prescription medications …
NHS England reinstates treatments to Cancer Drugs Fund
November 4, 2015Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NHS England
Five treatments in seven indications have been reinstated to Cancer Drugs Fund, as a result of negotiations between pharma companies …
Novo Nordisk invests in new insulin-filling facility
November 4, 2015Manufacturing and Production Denmark, Novo Nordisk, manufacturing, production
Novo Nordisk is investing 2.1 billion Danish Kroner (about £200m) in a new facility in Hillerød, Denmark, which will produce diabetes …
Merck appoints Laszlo Radvanyi as head of global immuno-oncology research
November 4, 2015Research and Development Laszlo Radvanyi, Merck
Dr Laszlo Radvanyi has joined Merck as senior vice president and head of research in immuno-oncology. The Merck Group says …
GSK plots return to growth with launch of 20 new drugs by 2020
November 4, 2015Research and Development, Sales and Marketing GSK, Sir Andrew Witty, financial results, product pipeline
GSK has set out plans to boost its flagging performance with the launch of up to 20 new drugs by …
Drugs later in development ‘winning the race to market’
November 4, 2015Research and Development R&D, drug approval, drug development, market exclusivity
Nearly all later entrants to drug classes were in clinical testing or regulatory review before first-in-class approval, according to the …
Pfizer approached GSK for takeover before Allergan
November 4, 2015Research and Development, Sales and Marketing Allergan, GSK, Pfizer, financial results, product pipeline
Pfizer had a takeover approach rejected by fellow pharma giant GlaxoSmithKline, before turning its attentions to Allergan, it has emerged. …
Bristol-Myers Squibb enters academic R&D tie-up
November 4, 2015Research and Development BMS, Bristol-Myers Squibb, Cardioxy, John Hopkins, acquisition, immunooncology, job losses
Bristol-Myers Squibb and The Johns Hopkins University have entered into a collaboration agreement, as part of the pharma firm’s rare …
Novo Nordisk forms academic partnership with Washington Uni
November 4, 2015Research and Development Novo Nordisk, diabetes, obesity
Novo Nordisk has launched a new research collaboration with researchers at the University of Washington, to develop new drugs for …
Putting off-patent drugs back to work
November 4, 2015Research and Development, Sales and Marketing Off-Patent Drugs Bill, Professor Paul Workman, The ICR, The ICR London, drug repurposing, patents
Six clinicians here at The Institute of Cancer Research, London, have joined colleagues from across the UK in writing to …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
